Evidence map›Paper›PMID 27909334›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2017

Emerging Epigenetic Therapies in Neuroscience: Focus on Bromodomain-Containing Drug Targets.

Claes Wahlestedt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Claes WahlestedtCenter for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA.

Funding

Vitamin D Concentration, Genetic Modifiers, and Parkinson DiseaseP50NS071674 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI VANCE, JEFFERY MARVIN · 2010 to 2015
$10.2M
Epigenetic Signaling Pathways Contributing to Alcohol DependenceR01AA023781 · NIAAA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HEILIG, MARKUS ALEXANDER, WAHLESTEDT, CLAES ROBERT · 2015 to 2019
$2.1M
Small Molecule Identification for the Nociceptin Receptor to Treat Cocaine AbuseR01DA035055 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WAHLESTEDT, CLAES ROBERT · 2012 to 2016
$1.7M
Long noncoding RNAs and chromatin regulation in cocaine addictionR21DA035592 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WAHLESTEDT, CLAES ROBERT · 2014 to 2015
$381k
NIAAA NIH HHS R01 AA023781NIDA NIH HHS R01 DA035055NIDA NIH HHS R21 DA035592NINDS NIH HHS P50 NS071674
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug DiscoveryEpigenesis, GeneticHumansNervous System Diseases

Identifiers

PMID27909334
PMCPMC5143503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.